Abstract:Objective To study the correlation between class Ⅲ β-tubulin expression and efficacy of tubulin-binding-based chemotherapy in advanced non-small cell lung cancer(NSCLC).Methods One hundred and twenty ⅢB/Ⅳ stage NSCLC patients were enrolled from January 2002 to December 2006.Expression of class Ⅲ β-tubulin was examined immunohistochemically in tumor samples obtained by bronchoscopy or lung puncture before treatment.All the patients were treated with 4 to 6 cycles of chemotherapy(taxane/cisplatin or vinorelbine/cisplatin regimen).Overall survival(OS),time to progression(TTP) and response rate(RR) were assessed after chemotherapy.Results Fifty-three patients finished the trail and could be evaluated.RR,TTP and OS of high expression of class Ⅲ β-tubulin group(n=31) were 9.4%,(170.06±71.45) days and(277.26±112.82) days,lower than 45.5%,(289.45±129.78)days and(457.32±207.12) days of low expression of class Ⅲ β-tubulin group(n=22),respectively(P<0.001).The expression of class Ⅲ β-tubulin had no correlation with age,gender,smoking,basic diseases,pathology,complications,family history and PS score.Conclusion The expression of class Ⅲ β-tubulin has correlation with the sensibility of tubuling-binding chemotherapy,and patients of low expression have longer TTP and OS than patients of high expression.Class Ⅲ β-tubulin has no correlation with clinical characteristics in patients with advanced NSCLC.

Class Ⅲ β-tubulin expression in advanced non-small cell lung cancer patients receiving tubulin-binding agents